Navigation Links
Tulane receives $15 million NIH contract to develop vaccine and treatment for deadly fever
Date:2/9/2010

The National Institute of Allergies and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a five-year contract totaling $15,254,919 to Tulane University for its ongoing efforts to treat and prevent Lassa fever, an often deadly viral disease that threatens hundreds of thousands of people annually in West Africa and is classified as a potential bioterrorism threat.

The contract will include collaboration between Tulane; Scripps Research Institute; The Broad Institute; Harvard University; the University of California at San Diego; Boston University; Autoimmune Technologies, LLC; Corgenix Medical Corporation and various partners in West Africa.

Dr. James Robinson, professor of pediatrics at Tulane University School of Medicine and principal investigator of the program, said researchers plan to evaluate antibodies from patients who were infected by the Lassa virus and recovered, to see if those antibodies might play a role in the development of a vaccine or treatment for the illness.

"This study will result in a fundamental understanding of the mechanisms of antibody responses and how they neutralize the Lassa virus," Robinson said. "We have assembled a very strong and diverse group of institutions to collaborate on this project."

In some areas of Sierra Leone, up to 16 percent of people admitted to hospitals have Lassa fever. Lassa fever is also associated with occasional epidemics, during which the fatality rate can reach 50 percent.

But Dr. Robert Garry, professor of microbiology and immunology at Tulane, who serves as program manager of the contract, sees hope.

"We have been very pleased with the results of our research efforts over the past five years," he said. "The diagnostic products we have developed have been shown to be remarkably effective in clinical settings in Africa, and will not only have a meaningful impact on health care in that part of the world, but will also fill a critical gap in bioterrorism defense. Now under the new NIH award, we will move to the next level allowing us to better treat the disease, or ultimately prevent it altogether."

Another team member, Dr. Daniel Bausch, associate professor of tropical medicine at Tulane University School of Public Health and Tropical Medicine, says that the group intends to expand this program to address other important infectious agents such as Ebola, Marburg and other hemorrhagic fever viruses that are of concern to the public health and bioterrorism preparedness communities.


'/>"/>

Contact: Arthur Nead
anead@tulane.edu
Tulane University
Source:Eurekalert

Related biology news :

1. Tulane receives grant to study limb regeneration
2. Carnegie Mellons John Kitchin receives early career award
3. Jedi Mind Receives Vast Media Coverage at CES in Las Vegas
4. University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium
5. GenWay Clinical Laboratory receives accreditation from College of American Pathologists
6. Editor of Springer classic human genetics reference receives prize
7. Lehigh University professor receives Astellas Award for arsenic groundwater remediation efforts
8. University of California, San Francisco, researcher receives ASBMB-Merck Award
9. IGC scientist receives prestigious EMBO installation grant
10. UT Southwestern receives $700,000 from HHMI to promote medical education of Ph.D. students
11. Einstein receives high-risk/high-reward cancer research funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
Breaking Biology News(10 mins):
(Date:6/22/2016)... ... June 22, 2016 , ... Quantitative ... business incubator and current participant in the Phase 1 Ventures program, is leveraging ... , Quantitative Radiology Solutions helps physicians make better treatment decisions by quantifying ...
(Date:6/22/2016)... (PRWEB) , ... June 21, 2016 , ... New light-based ... cutting into the tissue — promise to enable both compact, wearable devices for point-of-care ... even deeper under the skin. , Recent work and visionary future directions are detailed ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... that has developed a testing platform designed specifically ... the formation of their scientific advisory board (SAB). ... of directors, the SAB is chartered to advise ... infectious disease assay platform. Led by Dr. ...
(Date:6/22/2016)... June 22, 2016 On Tuesday, June ... 4,843.76, up 0.14%; the Dow Jones Industrial Average advanced 0.14% ... 2,088.90, up 0.27%. The gains were broad based as five ... has initiated coverage on the following equities: Minerva Neurosciences Inc. ... PTLA ), Trevena Inc. (NASDAQ: TRVN ), ...
Breaking Biology Technology: